| P50 | author | Immaculata Xess | Q88440930 |
| P2093 | author name string | Anant Mohan | |
| | Yubhisha Dabas | |
| P2860 | cites work | Laboratory detection and identification of Aspergillus species by microscopic observation and culture: the traditional approach. | Q51369487 |
| | Galactomannan in Bronchoalveolar Lavage Fluid | Q57559940 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | False positive galactomannan Platelia due to piperacillin-tazobactam | Q82869766 |
| | Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay | Q83881387 |
| | Aspergillus infections in the critically ill | Q84209947 |
| | Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia | Q84799074 |
| | Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome | Q24811601 |
| | Pulmonary aspergillosis: a clinical review | Q28246805 |
| | Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome | Q28264458 |
| | Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis | Q28540254 |
| | The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 |
| | Intensive care medicine research agenda on invasive fungal infection in critically ill patients | Q30235457 |
| | Clinical review: International comparisons in critical care - lessons learned | Q30416183 |
| | Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States | Q33703566 |
| | Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. | Q34430636 |
| | Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes | Q35131913 |
| | Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients | Q35575320 |
| | Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. | Q36102778 |
| | Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome | Q36686780 |
| | Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study | Q36886708 |
| | Serum galactomannan assay for diagnosis of probable invasive Aspergillosis in acute leukemia and hematopoietic stem cell transplantation | Q37150921 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Conventional or molecular measurement of Aspergillus load | Q37226612 |
| | Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients | Q37802029 |
| | Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. | Q39473672 |
| | Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study. | Q41038249 |
| | Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients | Q41998776 |
| | The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections | Q43125603 |
| | False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. | Q44688423 |
| | Aspergillus in the lower respiratory tract of immunocompetent critically ill patients | Q44886088 |
| | A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients | Q46059175 |
| | Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality | Q49124894 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | invasive aspergillosis | Q3625278 |
| | diagnostic marker | Q129938486 |
| P304 | page(s) | e0196196 | |
| P577 | publication date | 2018-04-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Serum galactomannan antigen as a prognostic and diagnostic marker for invasive aspergillosis in heterogeneous medicine ICU patient population | |
| P478 | volume | 13 | |